Simvastatin in the Prevention of Recurrent Pancreatitis: Design and Rationale of a Multicenter Triple-Blind Randomized Controlled Trial, the SIMBA Trial

Frontiers in Medicine

Bechien U. Wu¹  Pedro Zapater²  Pramoud K. Garg³  Georgios I. Papachristou⁴  Karina Cárdenas-Jaén⁵  Alicia Vaillo-Rocamora⁵  Enrique de-Madaria⁵  Vikesh K. Singh⁶  Ángel Gracia⁷ 

[1] Center for Pancreatic Care, Division of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, United States;Department of Clinical Pharmacology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India;Division of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH, United States;Pancreatic Unit, Department of Gastroenterology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Pancreatitis Center, Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, MD, United States;Pharmacy Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;

关键词: hydroxymethylglutaryl-CoA reductase inhibitors;    statins;    simvastatin;    acute pancreatitis;    chronic pancreatitis;    recurrent;    idiopathic;    prevention;   

DOI  :  10.3389/fmed.2020.00494

来源: Frontiers

【 授权许可】

CC BY